查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1976736

周边动脉疾病治疗市场：按产品类型、适应症、给药途径和最终用户划分 - 全球预测 2026-2032 年

Peripheral Arterial Disease Therapeutics Market by Product Type, Indication, Route Of Administration, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，周边动脉疾病治疗市场价值将达到 56 亿美元，到 2026 年将成长至 61.1 亿美元，到 2032 年将达到 103 亿美元，复合年增长率为 9.08%。

主要市场统计数据
基准年 2025 56亿美元
预计年份：2026年 61.1亿美元
预测年份 2032 103亿美元
复合年增长率 (%) 9.08%

全面概述周边动脉疾病的治疗方法，并从临床、营运和商业性因素的角度出发，探讨影响治疗路径和相关人员决策的因素。

周边动脉疾病处于血管病理学、治疗方法创新和不断发展的医疗服务模式的复杂交汇点。本执行摘要整合了多学科证据，重点阐述了临床实务、法规环境和商业策略之间的交集。以下说明将着重于从传统药物疗法到器械介入治疗的治疗方法，并结合医疗系统优先事项和以患者为中心的治疗结果，探讨这些进展。

程序创新、药物进步和数位化照护路径如何共同重新定义周边动脉疾病。

临床实务与科技的融合正在改变周边动脉疾病的诊断、治疗和管理。近年来，在影像技术、导管技术和辅助器械进步的支持下，微创血管内治疗技术发展迅速。伴随这些手术技术的进步，人们重新关注药物治疗策略，不再仅限于缓解症状，而是致力于降低重大心血管事件的发生率，这促使整个医学领域重新建构治疗目标。

根据 2025 年美国关税变化对治疗生态系统成本动态和营运连续性的影响，我们预测供应链调整、筹资策略和产品设计将会改变。

美国预计2025年的关税政策变化可能会影响周边动脉疾病治疗生态系统的多个环节，相关人员已开始为各种连锁反应做好准备。对进口医疗设备、药品和中间组件征收关税可能会增加专用导管、药物释放型球囊和诊断成像设备等设备的到岸成本。因此，製造商和医疗系统可能会调整筹资策略，并寻求透过使用替代供应商、近岸外包或加速生产本地化来降低风险。

整合产品子类别、临床适应症、医疗保健服务管道和给药途径的策略性细分洞察，对于指导开发和商业化选择至关重要。

深入了解患者族群特征、产品和通路对于将研发与商业化策略结合至关重要。所考虑的产品类型包括抗凝血剂、抗血小板药物、溶栓剂和血管扩张剂。抗凝血剂又可细分为直接口服抗凝血剂 (DOAC)、肝素和Warfarin；抗血小板药物包括阿斯匹灵、Clopidogrel和替格瑞洛；溶栓剂包括组织型胞浆素原原激活剂 (t-PA) 和尿激酶；血管扩张剂通常为Cilostazol和Pentoxifylline。这些差异会影响临床决策、处方集选择和术后管理，因为每个亚类都有其独特的动态、监测要求和交互作用特征。

美洲、欧洲、中东和非洲以及亚太地区的区域特征和战略意义决定了监管方法、证据需求和准入策略。

区域趋势对临床实践、监管预期和供应链结构有着深远的影响。在美洲，临床指引日益强调在关注肢体介入的同时，也要注重综合性的心血管风险降低，而医疗系统则需要在专科医生数量和不断增长的门诊量之间寻求平衡。该地区的支付模式也存在显着差异，这会影响新治疗方法的可及性和处方集时间。因此，优先创建真实世界证据和以支付方为中心的卫生经济学数据的策略，很可能在商业性谈判中获得支持。

如何透过伙伴关係、扩展终点和製造弹性将製药、医疗设备和数位解决方案策略融合起来，从而创造临床和商业性价值。

在周边动脉疾病治疗领域，各公司正采取多元化的策略，涵盖渐进式创新、平台开发和策略联盟。生物製药公司专注于研发差异化分子和具有复杂心血管获益特征的药物，以改善肢体功能并降低全身动脉粥状硬化风险。同时，医疗设备製造商正投资于新型涂层、导管设计和复合材料产品，以辅助药物治疗方案，并专注于提升手术效率、药物传递和耐用性。

产业领导者可采取切实可行的策略重点，加强供应链，扩大证据生成，整合数位医疗，以加速治疗方法的采用和支付方的接受。

产业领导者必须采取果断行动，将科学进步和营运转型转化为永续的竞争优势。首先，各机构应加快建构跨学科证据，将手术创新与心血管和肢体长期疗效联繫起来，从而增强其对支付方和医疗保健系统的价值提案。其次，价值链多元化和区域化生产模式可以降低关税波动风险，并提高对临床医生需求的应对力。投资模组化设备设计并从多个地区采购关键部件可以增强营运韧性。

采用方法严谨的调查方法，结合临床医师访谈、临床文献、监管分析和情境规划，以检验策略见解和建议。

本研究整合了一级资讯来源和二级资讯来源，对周边动脉疾病治疗领域进行了稳健且可重复的评估。一手调查包括对临床医生、医院采购经理、门诊手术中心管理人员和临床试验研究人员进行结构化访谈，以收集有关药物治疗方案和器械使用流程的实际资讯。这些定性研究结果辅以对公开临床试验註册资讯、同侪审查文献、监管指导文件和医疗技术评估的分析，以确保临床和监管方面的严谨性。

综合考虑临床进展、供应链压力和战略需求，我们确定了周边动脉疾病相关人员的短期优先事项。

周边动脉疾病的治疗涉及三大要素：不断发展的临床科学、不断变化的医疗保健格局以及复杂的商业性压力。该领域的特点是血管内治疗技术取得了显着进步，人们重新关注能够降低全身风险的抗血栓策略，并且越来越需要能够证明肢体持续保全和患者功能改善的证据。这些发展是在各地法规不尽相同以及关税可能导致供应链中断的背景下进行的，因此需要製造商和医疗服务提供者采取积极主动、全面的策略应对措施。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章周边动脉疾病治疗市场：依产品类型划分

  • 抗凝血剂
    • 口服直接抗凝血剂
    • 肝素
    • Warfarin
  • 抗血小板药物
    • 阿斯匹灵
    • Clopidogrel
    • 奇卡格雷洛
  • 溶栓剂
    • 组织型胞浆素原原激活剂
    • 尿激酶
  • 血管扩张剂
    • Cilostazol
    • Pentoxifylline

第九章周边动脉疾病治疗市场：依适应症划分

  • 严重下肢缺血
  • 间歇性跛行

第十章周边动脉疾病治疗药物市场：依给药途径划分

  • 口服
  • 肠外

第十一章周边动脉疾病治疗市场：依最终用户划分

  • 门诊手术中心
  • 医院
  • 专科诊所

第十二章周边动脉疾病治疗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章周边动脉疾病治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章周边动脉疾病治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国周边动脉疾病治疗市场

第十六章：中国周边动脉疾病治疗市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Alucent Biomedical Inc.
  • AnGes, Inc.
  • AngioDynamics, Inc.
  • ARCA biopharma, Inc.
  • B. Braun SE
  • Becton, Dickinson and Company
  • BIOTRONIK SE & Co. KG
  • Boston Scientific Corporation
  • Cook Group Incorporated
  • Helixmith Co., Ltd.
  • Koninklijke Philips NV
  • LeMaitre Vascular, Inc.
  • Medtronic PLC
  • Meril Life Sciences Pvt. Ltd.
  • MicroPort Scientific Corporation
  • REVA Medical, LLC
  • Terumo Corporation
  • Venturis Therapeutics, Inc.
  • WL Gore & Associates, Inc.
Product Code: MRR-69324464D29D

The Peripheral Arterial Disease Therapeutics Market was valued at USD 5.60 billion in 2025 and is projected to grow to USD 6.11 billion in 2026, with a CAGR of 9.08%, reaching USD 10.30 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.60 billion
Estimated Year [2026] USD 6.11 billion
Forecast Year [2032] USD 10.30 billion
CAGR (%) 9.08%

An integrated overview of peripheral arterial disease therapeutics that frames clinical, operational, and commercial drivers shaping treatment pathways and stakeholder decisions

Peripheral arterial disease represents a complex intersection of vascular pathology, therapeutic innovation, and shifting care delivery models. This executive summary synthesizes multidisciplinary evidence to illuminate where clinical practice, regulatory environments, and commercial strategy converge. The narrative that follows focuses on therapeutic modalities ranging from classical pharmacotherapies to device-based interventions, and frames these developments against the backdrop of health system priorities and patient-centric outcomes.

The clinical burden of limb ischemia and intermittent claudication continues to drive demand for both established agents and next-generation therapeutics. Consequently, clinicians and payers increasingly evaluate interventions on procedural efficacy, long-term limb salvage, and cardiovascular risk reduction. Moreover, the patient journey now commonly involves outpatient pathways, integrated wound care, and coordinated vascular teams that emphasize functional recovery alongside survival metrics. Given these realities, stakeholders must integrate clinical evidence with operational feasibility and evolving reimbursement paradigms to optimize therapeutic adoption and patient outcomes.

How procedural innovation, pharmacologic evolution, and digital care pathways are jointly redefining standards of treatment and long-term management for peripheral arterial disease

Clinical practice and technology are converging to create transformative shifts in how peripheral arterial disease is diagnosed, treated, and managed. In recent years, minimally invasive endovascular techniques have advanced rapidly, supported by improvements in imaging, catheter technologies, and adjunctive devices. These procedural advances have coincided with a renewed focus on pharmacologic strategies that extend beyond symptom relief to reduce major adverse cardiovascular events, thereby reframing therapeutic objectives across care settings.

Concurrently, digital health and remote monitoring are changing post-procedural follow-up and chronic disease management. Telemedicine-facilitated vascular clinics and wearable-enabled gait and perfusion monitoring complement traditional vascular labs, enabling earlier detection of deterioration and tailored rehabilitation programs. At the same time, regenerative medicine and targeted biologics continue to progress through clinical development, promising alternative pathways for patients with limited revascularization options. Finally, care delivery has shifted toward ambulatory settings for selected procedures, increasing the strategic importance of ambulatory surgical centers and specialty clinics as sites of care. Together, these factors are driving integrated care models that prioritize value, patient experience, and longitudinal outcomes.

Anticipating supply chain adjustments, procurement strategies, and product design shifts as U S tariff changes in 2025 reshape cost dynamics and operational resilience in the therapeutic ecosystem

Changes in U.S. tariff policy projected for 2025 have the potential to affect multiple elements of the peripheral arterial disease therapeutic ecosystem, and stakeholders are already preparing for varied ripple effects. Tariffs on imported medical devices, pharmaceuticals, and intermediate components may increase landed costs for devices such as specialized catheters, drug-coated balloons, and diagnostic imaging equipment. As a result, manufacturers and health systems may reassess sourcing strategies, seeking to mitigate exposure through alternative suppliers, nearshoring, or accelerated localization of production.

Moreover, tariffs can influence the supply chain timing and inventory strategies adopted by hospitals and ambulatory surgical centers. In the near term, purchasing teams may expand buffer inventories or renegotiate supply contracts to stabilize access to critical consumables. Over time, manufacturers could revise pricing models or shift manufacturing footprints, which in turn would affect procurement cycles and capital planning for facility upgrades. From a research and development perspective, tariff-driven cost pressures may reorient investment priorities toward cost-efficient innovations and modular device designs that rely less on tariff-exposed components. Finally, regulatory and payer responses may evolve to address affordability and access, prompting collaborative initiatives to preserve continuity of care without compromising clinical standards.

Strategic segmentation insights that integrate product subclasses, clinical indications, care delivery channels, and administration routes to inform development and commercialization choices

A granular understanding of patient, product, and channel segmentation is essential to align research, development, and commercialization strategies. Product type considerations span anticoagulants, antiplatelet agents, thrombolytics, and vasodilators, with anticoagulants subdividing into direct oral anticoagulants, heparin, and warfarin while antiplatelet agents encompass aspirin, clopidogrel, and ticagrelor; thrombolytics include tissue plasminogen activator and urokinase, and vasodilators are typified by cilostazol and pentoxifylline. These distinctions influence clinical decision-making, formulary placement, and post-procedural management, since each subclass carries unique pharmacodynamics, monitoring requirements, and interaction profiles.

Indication-based segmentation discriminates between critical limb ischemia and intermittent claudication, which differ markedly in disease trajectory, therapeutic urgency, and multidisciplinary care needs. End-user channels range from ambulatory surgical centers to hospitals and specialty clinics, and the choice of setting impacts device selection, staffing models, reimbursement pathways, and length of stay. Finally, route of administration - oral versus parenteral - intersects with adherence considerations, outpatient feasibility, and resource allocation for monitoring and administration. By integrating these segmentation axes, stakeholders can prioritize clinical development programs, tailor marketing messages, and design access strategies that address the nuanced needs of clinicians, payers, and patients.

Regional contours and strategic implications across the Americas, Europe Middle East & Africa, and Asia-Pacific that dictate regulatory approaches, evidence needs, and access strategies

Regional dynamics exert a powerful influence on clinical practice, regulatory expectations, and supply chain architecture. In the Americas, clinical guidelines increasingly emphasize integrated cardiovascular risk reduction alongside limb-focused interventions, while health systems balance specialist capacity with growing outpatient procedural volumes. This region also exhibits significant heterogeneity in payer models, which affects formulary access and adoption timelines for novel therapies. Consequently, strategies that prioritize real-world evidence generation and payer-centric health economic dossiers will find traction in commercial conversations.

Across Europe, Middle East & Africa, regulatory harmonization and varying reimbursement pathways shape market entry strategies and clinical adoption rates. In many markets, authorities place a premium on long-term outcomes and cost-effectiveness data, which can lengthen time to wide adoption but also create durable value propositions for therapies that demonstrate limb salvage and cardiovascular benefit. In contrast, Asia-Pacific markets are characterized by rapid uptake of minimally invasive procedures, expanding interventional capacity, and strong domestic manufacturing ambitions, which together influence pricing dynamics and partnership models. Recognizing these regional contours allows sponsors to sequence market entry, localize evidence generation, and optimize manufacturing footprints to meet distinct regulatory and commercial requirements.

How pharmaceutical, medical device, and digital solution strategies are converging through partnerships, expanded endpoints, and manufacturing resilience to capture clinical and commercial value

Companies operating in the peripheral arterial disease therapeutic space are pursuing diversified strategies that span incremental innovation, platform development, and strategic partnerships. Biopharmaceutical firms emphasize differentiated molecules and composite cardiovascular benefit profiles that address both limb outcomes and systemic atherosclerotic risk. At the same time, medical device manufacturers focus on procedural efficiency, deliverability, and durability, investing in novel coatings, catheter design, and combination products that complement pharmacologic regimens.

Across the industry, collaboration between pharma and device players is increasingly common, enabling bundled value propositions that align procedural and medical management. Additionally, growing interest in digital therapeutics and remote monitoring has catalyzed partnerships with software and analytics providers to enhance post-procedural care and patient engagement. From a corporate strategy perspective, companies are prioritizing regulatory alignment early in development, expanding clinical endpoints to include functional and quality-of-life measures, and pursuing manufacturing resilience to mitigate tariff and supply chain risks. These approaches collectively reflect a shift toward holistic solutions that extend beyond single-modality interventions.

Actionable strategic priorities for industry leaders to fortify supply chains, amplify evidence generation, and integrate digital care to accelerate therapy adoption and payer acceptance

Industry leaders must act decisively to convert scientific advances and operational shifts into sustainable competitive advantage. First, organizations should accelerate cross-disciplinary evidence generation that links procedural innovation with long-term cardiovascular and limb outcomes, thereby strengthening value propositions for payers and health systems. Secondly, supply chain diversification and regional manufacturing options will reduce exposure to tariff volatility and improve responsiveness to clinician demand. Investing in modular device designs and procuring critical components from multiple geographies will enhance operational resilience.

Furthermore, companies should integrate digital health solutions to support adherence, remote monitoring, and rehabilitation pathways that improve functional recovery and reduce readmissions. Engaging regulators and payers early, and designing trials that incorporate patient-reported outcomes and health economic endpoints, will facilitate reimbursement readiness. Finally, targeted commercial strategies that reflect segmentation across product subtypes, indications, care settings, and routes of administration will maximize uptake; aligning sales and clinical education programs to ambulatory surgical center workflows and hospital procurement practices will accelerate diffusion of novel therapies.

A methodologically rigorous approach combining clinician interviews, clinical literature, regulatory analysis, and scenario planning to validate strategic insights and recommendations

This research synthesizes primary and secondary sources to deliver a robust, reproducible assessment of the peripheral arterial disease therapeutics landscape. Primary research included structured interviews with clinicians, hospital procurement leaders, ambulatory surgical center administrators, and clinical trial investigators to capture frontline experiences with pharmacologic regimens and device workflows. These qualitative insights were supplemented with analyses of publicly available clinical trial registries, peer-reviewed literature, regulatory guidance documents, and health technology assessments to ensure clinical and regulatory rigor.

The analytical framework incorporates a multi-axis segmentation approach, scenario planning for supply chain and tariff exposures, and thematic triangulation across clinical outcomes, payer requirements, and commercial pathways. Data validation processes involved cross-referencing interview findings with published procedure utilization trends and device approval histories. Finally, sensitivity checks and expert reviews helped refine strategic implications and recommendations, ensuring the report supports decision-makers seeking evidence-based pathways for development, commercialization, and operations within this evolving therapeutic area.

Synthesis of clinical advances, supply chain pressures, and strategic imperatives that together define the near-term priorities for peripheral arterial disease stakeholders

Peripheral arterial disease therapeutics sits at the intersection of evolving clinical science, changing care settings, and complex commercial pressures. The landscape is characterized by meaningful advances in endovascular technology, renewed emphasis on antithrombotic strategies that reduce systemic risk, and increasing demand for evidence that demonstrates durable limb salvage and improved patient function. These developments occur against a backdrop of regional regulatory diversity and potential tariff-driven supply chain disruptions, which together require proactive and integrated strategic responses from manufacturers and providers.

In sum, stakeholders that align product development with payer evidence needs, invest in supply chain agility, and leverage digital care to enhance outcomes will be best positioned to navigate the coming years. By prioritizing multidisciplinary evidence generation and adaptive commercialization models, organizations can translate scientific innovation into sustained clinical benefit and commercial viability. The result will be a more resilient, patient-centered therapeutic ecosystem for individuals living with peripheral arterial disease.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Peripheral Arterial Disease Therapeutics Market, by Product Type

  • 8.1. Anticoagulants
    • 8.1.1. Direct Oral Anticoagulants
    • 8.1.2. Heparin
    • 8.1.3. Warfarin
  • 8.2. Antiplatelet Agents
    • 8.2.1. Aspirin
    • 8.2.2. Clopidogrel
    • 8.2.3. Ticagrelor
  • 8.3. Thrombolytics
    • 8.3.1. Tissue Plasminogen Activator
    • 8.3.2. Urokinase
  • 8.4. Vasodilators
    • 8.4.1. Cilostazol
    • 8.4.2. Pentoxifylline

9. Peripheral Arterial Disease Therapeutics Market, by Indication

  • 9.1. Critical Limb Ischemia
  • 9.2. Intermittent Claudication

10. Peripheral Arterial Disease Therapeutics Market, by Route Of Administration

  • 10.1. Oral
  • 10.2. Parenteral

11. Peripheral Arterial Disease Therapeutics Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Hospitals
  • 11.3. Specialty Clinics

12. Peripheral Arterial Disease Therapeutics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Peripheral Arterial Disease Therapeutics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Peripheral Arterial Disease Therapeutics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Peripheral Arterial Disease Therapeutics Market

16. China Peripheral Arterial Disease Therapeutics Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Alucent Biomedical Inc.
  • 17.7. AnGes, Inc.
  • 17.8. AngioDynamics, Inc.
  • 17.9. ARCA biopharma, Inc.
  • 17.10. B. Braun SE
  • 17.11. Becton, Dickinson and Company
  • 17.12. BIOTRONIK SE & Co. KG
  • 17.13. Boston Scientific Corporation
  • 17.14. Cook Group Incorporated
  • 17.15. Helixmith Co., Ltd.
  • 17.16. Koninklijke Philips N.V.
  • 17.17. LeMaitre Vascular, Inc.
  • 17.18. Medtronic PLC
  • 17.19. Meril Life Sciences Pvt. Ltd.
  • 17.20. MicroPort Scientific Corporation
  • 17.21. REVA Medical, LLC
  • 17.22. Terumo Corporation
  • 17.23. Venturis Therapeutics, Inc.
  • 17.24. W. L. Gore & Associates, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY HEPARIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY HEPARIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY HEPARIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY WARFARIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY WARFARIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY WARFARIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ASPIRIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ASPIRIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ASPIRIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY CLOPIDOGREL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY CLOPIDOGREL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY CLOPIDOGREL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TICAGRELOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TICAGRELOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TICAGRELOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY UROKINASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY UROKINASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY UROKINASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY CILOSTAZOL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY CILOSTAZOL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY CILOSTAZOL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PENTOXIFYLLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PENTOXIFYLLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PENTOXIFYLLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY CRITICAL LIMB ISCHEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY CRITICAL LIMB ISCHEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY CRITICAL LIMB ISCHEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INTERMITTENT CLAUDICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INTERMITTENT CLAUDICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INTERMITTENT CLAUDICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. GCC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GCC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. GCC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2032 (USD MILLION)
  • TABLE 159. GCC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2032 (USD MILLION)
  • TABLE 160. GCC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2032 (USD MILLION)
  • TABLE 161. GCC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2032 (USD MILLION)
  • TABLE 162. GCC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 163. GCC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 164. GCC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. G7 PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. G7 PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. G7 PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2032 (USD MILLION)
  • TABLE 186. G7 PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2032 (USD MILLION)
  • TABLE 187. G7 PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2032 (USD MILLION)
  • TABLE 188. G7 PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2032 (USD MILLION)
  • TABLE 189. G7 PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 190. G7 PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 191. G7 PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. NATO PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. NATO PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. NATO PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2032 (USD MILLION)
  • TABLE 195. NATO PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2032 (USD MILLION)
  • TABLE 196. NATO PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2032 (USD MILLION)
  • TABLE 197. NATO PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2032 (USD MILLION)
  • TABLE 198. NATO PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 199. NATO PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 200. NATO PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)